共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
3.
酶替代治疗戈谢病72例 总被引:10,自引:0,他引:10
目的通过对戈谢病患者的用药跟踪监测,综合评估酶制剂伊米苷酶(Imiglucerase)替代疗法(ERT)治疗戈谢病的效果。方法 1999年5月至2005年10月,ERT 治疗戈谢病72例,男46例、女26例,年龄1岁4个月~22岁。Ⅰ型57例、Ⅱ型2例、Ⅲ型13例。伊米苷酶初剂量60 U/kg,每2周1次静脉滴注,2年后剂量改为45 U/kg。每用药3~6个月,对患者进行身高、体重、血常规、肝脾容积测定、长骨 X 线等检查。结果 3例失访,4例死亡,正接受治疗65例。ERT 治疗12个月起,未切除脾脏患者的 Hb 和血小板值显著增加(P<0.01);ERT 治疗30个月时,已切除脾脏患者的Hb 值明显增加(P<0.01),而血小板值在 ERT 治疗中无明显改变(P>0.05)。肝、脾体积随时间显著回缩(P<0.01),治疗24个月肝脏缩小(39±17)%、脾脏缩小(59±21)%。治疗12个月,2~12岁患儿身高增长(8.6±4.3)cm,体重增加(2.6±1.7)kg,12~18岁患儿身高增长(5.2±3.9)cm,体重增加(4.5±3.3)kg。复查骨 X 线征象无明显改变、16例合并骨痛经治疗3个月即缓解;Ⅱ、Ⅲ型神经系统症状无改善;全部病例未发现严重的毒副作用。结论 ERT 可改善戈谢病患者全身症状:纠正贫血、血小板减少,使肝脾体积回缩,体格发育,骨痛缓解,从而提高其生存质量。 相似文献
4.
Background The natural history of focal splenic lesions in paediatric Gaucher disease (GD) is unknown and these lesions are thought to
persist despite enzyme replacement therapy (ERT).
Objective To assess the prevalence, evolution and resolution of splenic nodules in a cohort of paediatric Gaucher patients treated with
ERT.
Materials and methods The US findings in 37 children with GD were retrospectively reviewed. A total of 28 children underwent serial abdominal US
examinations as part of their initial assessment and during routine follow-up. All patients received ERT.
Results Six children (21%) had splenic nodules on US examination, either at presentation or on follow-up examination. In all six patients,
the nodules had resolved on follow-up imaging, with resolution taking 17 months to 4 years 8 months. Two sets of siblings
developed nodules that resolved over a similar time period.
Conclusion Disappearance of focal splenic lesions in children with GD during follow-up has not been previously reported. The development
of new focal splenic lesions in children with GD whilst on ERT has not been previously documented. 相似文献
5.
Arıkan-Ayyıldız Z Yuce A Uslu-Kızılkan N Demir H Gurakan F 《Pediatric blood & cancer》2011,56(4):664-666
Hyperimmunoglobulinemia is documented in patients with Gaucher disease of all ages. We investigated the frequency of hyperimmunoglobulinemia in 12 pediatric patients with type I and III Gaucher disease and the effects of enzyme replacement therapy on these abnormalities. The incidence of hyperimmunoglobulinemia was 77%, 66%, and 60% at the diagnosis, before and after ERT, respectively. Immunoglobulin G abnormalities were the most commonly seen isotype abnormality. After enzyme replacement therapy normalization of IgA and IgM levels were recorded but decline in IgG levels was less likely to occur. This study indicated the higher frequency of hyperimmunoglobulinemia in pediatric Gaucher patients. 相似文献
6.
7.
Goker-Alpan O Schiffmann R Park JK Stubblefield BK Tayebi N Sidransky E 《The Journal of pediatrics》2003,143(2):273-276
Neuronopathic Gaucher disease, classically divided into two types, can have a continuum of phenotypes, often defying categorization. Nine children had an intermediate phenotype characterized by a delayed age of onset but rapidly progressive neurological disease, including refractory seizures and oculomotor abnormalities. There was genotypic heterogeneity among these patients. 相似文献
8.
Background: Gaucher disease type 1 (GD1) was the first lysosomal storage disorder for which an effective enzyme replacement therapy was developed. We describe the management of eight GD1 patients in Slovenia who were diagnosed between the ages of 2 and 15 years. Methods: Patients were individually assessed to establish initial enzyme doses and monitored frequently to determine the effects of long‐term enzyme dose regimens. Outcomes up to 10 years after long‐term treatment are described by changes in the Zimran severity score index, chitotriosidase and acid phosphatase levels, and after 2001, bone parameters (DEXA bone mineral density scores and the MRI bone marrow burden score). Results: Following the initiation of enzyme therapy with individualized dose regimens (range 25–56 U/kg/14 days) and followed by a gradual reduction of doses (range 12–35 U/kg/14 days) during long‐term maintenance, disease status improved in all patients as measured by the Zimran severity score index (from a mean of 11.25 [median 11.5] before therapy to a mean of 4.12 [median 3.5] at last report). Anemia and leucopenia resolved in all patients, chitotriosidase and acid phosphatase levels decreased in all patients (and by over 75% in six patients) within 1 year of treatment. Bone marrow burden scores improved in all monitored patients and DXA scores improved in six of seven monitored patients. Conclusions: We conclude that enzyme therapy with relatively low, individualized dose regimens is well‐tolerated and effective in children and young adults with GD1 disease, who are regularly monitored for changes in disease status. 相似文献
9.
To determine treatment effects in the unique and previously internationally unreported Japanese paediatric patient population
with Gaucher disease (GD), we analysed six response parameters among 13 patients given enzyme replacement therapy (ERT). Also
to obtain insights into optimising maintenance dosing, through subgroup analysis we retrospectively examined effects of three
ERT dose reduction schedules from a starting regimen of 60 U/kg of body weight every 2 weeks. Our patients included 11 males
and two females, 11 individuals with possible type 1 and two individuals with type 3b GD, six individuals with the L444P/F2131
genotype and five with the L444P/L444P genotype, and five who had been splenectomised. Despite different mutation prevalence,
Japanese patients with GD, like their counterparts from other ethnic groups, generally benefitted from ERT. However, early
and marked ERT dose reduction (from 60 U/kg to 30 or 15 U/kg every 2 weeks within ≤6 months) was associated with insufficient
improvement of mean haemoglobin level and relative height and with insufficient improvement or worsening of platelet count.
Only the subgroup given 60 U/kg of ERT every 2 weeks for 36 months had significant improvement in mean haemoglobin, platelet
count, angiotensin-converting enzyme and acid phosphatase levels and relative height at 36 months.
Conclusion These data suggest that long-term high dose enzyme replacement therapy may be required to obtain sufficient improvement to
maintain health among paediatric patients with severe Gaucher disease.
Received: 12 April 2000 / Accepted: 25 May 2000 相似文献
10.
Gaucher disease is the most prevalent inherited lysosomal storage disorder caused by deficiency of β-glucocerebrosidase enzyme. Clinically, 3 forms of Gaucher disease are recognized, of which type 1 is the mild to moderately severe, slowly progressive, nonneuropathic form. Bleeding disorders in Gaucher disease are believed to be due to thrombocytopenia but there may be additional factors that influence coagulation and fibrinolysis in Gaucher disease patients. The aim of the present work was to study some coagulation parameters in the Egyptian children with type 1 Gaucher disease. Five newly diagnosed patients and another 5 patients on enzyme replacement therapy (ERT) were enrolled in the study. Their coagulation profile, including coagulation factors, was evaluated. The results showed that in newly diagnosed cases factors II and VII were deficient in 40%, factor V was deficient in 20%, and all the cases had low levels of serum fibrinogen. In patients on ERT, factors VII and VIII were deficient in 60%, factor XI was deficient in 40% and factors V, X, and XII were deficient in 20% of cases. In conclusion, Egyptian patients with type 1 Gaucher disease, whether newly diagnosed or receiving enzyme replacement therapy, experience coagulation factor abnormalities regardless the clinical expression of bleeding diathesis. This should be taken into consideration before these patients are subjected to surgery for, e.g., splenectomy, which is common in these patients. 相似文献
11.
Erikson A Forsberg H Nilsson M Aström M Månsson JE 《Acta paediatrica (Oslo, Norway : 1992)》2006,95(3):312-317
Aim: To study the long-term effects of enzyme replacement therapy on the neurological signs of chronic neuronopathic Gaucher disease and to evaluate some biochemical parameters for monitoring the treatment. Methods: Eight patients from the Norrbottnian cohort were followed during 10 y of treatment. They were followed with regular clinical observations, biochemical tests and psychometric testing. Results: After the start of treatment, their general well-being improved and was stable during the follow-up. In three of the patients there were some indications of slow neurological deterioration. The mean results of psychometric testing did not decrease. Glucosylceramide and chitotriosidase levels were useful in monitoring the treatment. The chemokine CCL18 also seems to be a useful parameter for future monitoring.
Conclusions: Enzyme replacement therapy seems to slow down further neurological and mental deterioration in mild chronic neuronopathic (type 3) Gaucher disease. 相似文献
Conclusions: Enzyme replacement therapy seems to slow down further neurological and mental deterioration in mild chronic neuronopathic (type 3) Gaucher disease. 相似文献
12.
TAKAHIRO UEDA YOSHITAKA FUKUNAGA MAKOTO MIGITA ATSUSHI WATANABE KIYOSHI KANEKO TOSHISADA MORITA MASAO YAMAMOTO 《Pediatrics international》1996,38(3):260-264
In recent years, enzyme replacement therapy has been shown to be useful for the treatment of Gaucher disease. A 10 year old Japanese boy with Gaucher disease underwent splenectomy at the age of 5 years and received enzyme replacement therapy from the age of 6 years. He had avascular necrosis of the bilateral femoral heads, which was not seen at the beginning of the therapy, without deterioration of hematological variables during maintenance therapy. The enzyme dosage was increased from 20 to 120 IU/kg per month resulting in an improvement of the clinical symptoms and bone lesion. In enzyme replacement therapy, dose increase is considered to be essential for improvement in bone disease; however, it is important to watch for the development of bone lesion. 相似文献
13.
Hyperimmunoglobulinemia, and other manifestations of B-cell stimulation, have been reported frequently in adults with type 1 Gaucher disease. We investigated the occurrence of hyperimmunoglobulinemia in 23 pediatric patients with type 1 Gaucher disease and studied the effects of early initiation of alglucerase/imiglucerase therapy on these abnormalities. We found that the incidences of increased levels of IgG, IgA, and IgM at pediatric age, as observed in our patients, were 3.2-fold, 4.3-fold and 5.1-fold higher, respectively, than the incidence in adult patients, and correspond with disease severity. Seventy-one percent of our pediatric patients had elevation of more than 1 immunoglobulin isotype, and 38% had elevations in all 3 isotypes. With sustained enzyme replacement therapy, substantial improvement, or normalization of IgA and IgM levels were obtained in most patients, while decline in IgG levels was less likely to occur. The presence of hyperimmunoglobulinemia in the majority of our pediatric patients suggests that early-onset production of immunostimulatory mediators by activated macrophages may be an important contributing factor, rather than disarrangements caused by long-standing glucocerebrosidase accumulation. In theory, early enzyme replacement therapy initiation may prevent antigenic stimulation and cytokine production, and reduce hyperimmunoglobulinemia and lymphatic neoplastic diseases in patients with type 1 Gaucher disease. 相似文献
14.
Sunita Bijarnia Peter Shaw Anne Vimpani Robert Smith Verity Pacey Helen O'Grady John Christodoulou David Sillence 《Journal of paediatrics and child health》2009,45(7-8):469-472
We report the long-term follow-up of successful treatment of mucopolysaccharidosis type I H (MPS IH, Hurler syndrome) with combined enzyme replacement therapy and haematopoietic progenitor stem cell transplant. 相似文献
15.
HIROYUKI IDA OWEN M RENNERT TAKERU ITO KIHEI MAEKAWA YOSHIKATSU ETO 《Pediatrics international》1996,38(3):233-236
Five fatal cases of Japanese patients with type 1 Gaucher disease were studied. The causes of death included hemorrhage secondary to esophageal varices (two cases), respiratory distress (one case), hepatic failure (one case) and postoperative sepsis (one case). All of the patients had previous splenectomies, four patients had bone involvement and hepatic cirrhosis. The identified Gaucher genotypes were 1448C/1213G, 1603T/1603T, 1448C/1390G, ?/? and 1213G/1213G. The prognosis of type 1 Gaucher disease is generally good. We propose that patients with a similar clinical course and genotype to those presented in the present study should receive prompt comprehensive treatment. Patients with the 1213G mutation, pulmonary and liver involvement and a previous splenectomy should be considered as candidates for early vigorous treatment. 相似文献
16.
The incidence and severity of osteolytic bone changes in patients with chronic (Type I) Gaucher disease splenectomized in the first decade of life were compared to those in patients of the same age group and similar degree of severity of the disease in whom the spleen remained intact at least until the second half of the second decade. The size of the spleen, measured by palpation, was used as an index of severity. In the splenectomized group osteolytic changes appeared within a few months following splenectomy in six out of eight cases. The changes were severe in five cases and moderate in one. In contrast, in the non-splenectomized group, evidence of bone destruction was found in two out of eight patients and classified as mild in both cases. Furthermore, in three patients in this group, who remained free of bone destruction until splenectomy in the second half of the second decade, osteolytic lesions appeared soon after the operation. Children with chronic Gaucher disease can be spared a great deal of suffering caused by bone disease, if splenectomy is avoided or postponed as far as possible.Abbreviation CGD
chronic, nonneuropathic (Type I) Gaucher disease 相似文献
17.
目的分析法布里病患儿的临床特点及使用酶替代药物治疗基本情况。方法对2014年1月至2020年7月间浙江大学医学院附属儿童医院确诊的4例法布里病患儿的临床资料、实验室检查、基因变异及治疗进行回顾性分析。临床观察其酶替代药物阿加糖酶β治疗的效果。结果 4例患儿(男2例、女2例)年龄12.4(6.0~16.8)岁,临床表现各异,其中肢端疼痛1例、少汗2例、尿崩1例,均有左心室肥厚和尿检异常,但均未发现典型皮疹及听力异常。4例患儿均结合临床症状、体征、家族史,通过α-半乳糖苷酶A酶活性、基因检测结果明确诊断。共检出3个GLA基因错义变异 c.424T>C(p.C142R)、c.335G>A(p.R112H)和c.644A>G(p.N215S)。其中前2个变异为经典型法布里病患者变异位点,后者多表现为迟发型但亦有经典型的报道。例1使用阿加糖酶β用量为每次1 mg/kg静脉泵注,每2周用药1次。患儿诉用药后疼痛强度有缓解,少汗症状得到改善。患儿在最初的2个月输注阿加糖酶β过程中未发生严重不良反应,在输注阿加糖酶β 3次后24 h尿蛋白升至1 015.6 mg,未予处理,1周后复查降至正常。结论法布里病在儿童期临床表现多样,需要多学科联合协同诊断并探讨酶替代治疗的时机,阿加糖酶β治疗患儿短期严重不良反应少见。 相似文献
18.
Although rarely they are a normal variant in children, significant defects in the medial aspect of the proximal humeral metaphysis occur in patients with Gaucher disease due to cortical infiltration and erosion of the periosteum by Gaucher cells. Such changes may lead to pathological fractures in Gaucher patients. These crescentic erosions resolved in a 19-year-old patient with type-1 Gaucher disease following enzyme replacement therapy. 相似文献
19.
Fowler DJ Weber MA Anderson G Malone M Sebire NJ Vellodi A 《Fetal and pediatric pathology》2006,25(5):241-248
The classical ultrastructural features of Gaucher disease include large numbers of intracytoplasmic, membrane-bound lysosomal inclusions containing characteristic tubular structures on an electron-lucent background, representing the periodic acid schiff (PAS)--positive Gaucher cells identifiable on light microscopy. Following enzyme replacement therapy (ERT), many of the manifestations of the condition are ameliorated, but persistent mesenteric lymphadenopathy has been reported, the ultrastructural features of which previously have not been described. Two children, aged 4 and 8 years old, respectively, both presented with persistent abdominal lymphadenopathy whilst receiving ERT for Gaucher disease. Needle core biopsies were carried out, that demonstrated collections of macrophages and only scattered storage-type cells on light microscopy. PAS staining was negative in one case and only focally positive in the other. Electron microscopic examination, however, confirmed the cells represented macrophages, the cytoplasm of which contained scattered abnormal inclusions containing occasional twisted tubular structures of the type reported in classic Gaucher disease. ERT in Gaucher disease appears to reduce accumulation of the metabolic products at many sites. But for uncertain reasons, abdominal lymphadenopathy may occur containing macrophages that do not form granulomas or classic Gaucher cells on light microscopy. These probably represent incomplete clearance, incomplete/partial enzyme replacement, or possibly an unusual response to a relatively small amount of storage material. 相似文献
20.
Megachemotherapy followed by autologous stem cell transplantation in children with Ewing's sarcoma 总被引:2,自引:0,他引:2
Drabko K Zawitkowska-Klaczynska J Wojcik B Choma M Zaucha-Prazmo A Kowalczyk J Gorczynska E Toporski J Kałwak K Turkiewicz D Chybicka A 《Pediatric transplantation》2005,9(5):618-621
Twenty-one children with high-risk Ewing's tumor received high-dose chemotherapy with a PBSCT. Aim of the study was evaluation of efficiency and safety of this procedure. All but three patients have meta-static disease at presentation. There were 11 females and the median age at diagnosis was 12 yr (range 4.5-18 yr). Megachemotherapy consisted of melphalan 140 mg/m2/busulfan 16 mg/kg in 12 patients, melphalan 140 mg2/treosulfan 10.0 g/m2 in two patients and melphalan with other drugs in seven patients. Eight of 11 patients transplanted in CR survived with a median follow-up 24 month (range 14-60) and probability of 2-year OS is 0.68 and DFS is 0.63. There was no severe regimen-related toxicity in this group. Children transplanted without remission died: Two of them due to transplant related causes and eight had progression of disease in a median time 7 month after PBSCT. Megachemotherapy with PBSCT is a safe procedure in children with Ewing's sarcoma in remission. Autologos transplantation in children with metastatic Ewing's sarcoma seems to improve their outcome. Patients with Ewing's sarcoma, resistant to conventional therapy and with recurrent disease did not benefit from megachemotherapy. New approaches such as anti-tumor vaccination or using of imatinib are reasonable to introduce in patients with relapsed or resistant to therapy Ewing's tumor. 相似文献